

Eluvia Meta-Analysis

Performance of stenting in femoropopliteal disease: Systemic review and meta-analysis of proportions.



OBJECTIVE

Systematically evaluate and analyze outcomes of four common stent types in femoropopliteal artery disease.

STUDY DESIGN

- Systematic literature review and meta-analysis of proportions
- Pooled proportions estimated with random-intercept logistic regression model
- Knapp-Hartung adjustments to calculate the 95% confidence interval around the pooled effect

INCLUSION CRITERIA

- PubMed search January 1, 2009 – July 1, 2024
- Studies of patients treated for SFA lesions or PAD treated with a vascular stent of interest ≥ 50 patients

STUDY SELECTION

- 142 articles
- 52,017 patients
- 27.5% core lab adjudication


STENT TYPES ANALYZED

- Boston Scientific Eluvia™ Drug-Eluting Stent**
(PB-PES: polymer-based paclitaxel eluting stent)
- Cook Zilver™ PTX**
(PF-PCS: polymer-free paclitaxel-coated stent)
- GORE® Viabahn® covered vascular stent graft**
(CVS)
- Bare Metal Stents: self-expanding nitinol stents, including interwoven stent (BMS)**


Eluvia DES demonstrated consistently greater primary patency and TLR outcomes compared to all other stent types.

Eluvia DES demonstrated consistently greater primary patency and TLR outcomes at 12 and 24 months, compared with Zilver PTX, Viabahn covered stent and self expanding nitinol stents (including interwoven stents) with no difference in mortality rates.

PRIMARY PATENCY




TARGET LESION REVASCULARIZATION




Eluvia DES is the definitive treatment choice for long, complex lesions.

In contrast to comparative stents, Eluvia DES primary patency rates did not decline in long lesions (mean length ≥ 150mm) at 12 and 24 months and remained superior compared with all other stent types.



*No Viabahn studies in the “short” lesion category.



*No Viabahn studies in the “short” lesion category.

1. Holden, A. Performance of Stenting in Femoropopliteal Disease: Systematic Literature Review and Meta-analysis of Proportions. Presented at Charing Cross 2025.
ELUVIA Drug-Eluting Vascular Stent System

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

No decline in Eluvia performance between short and long lesion length groups

More pronounced difference between Eluvia and other stent types for long lesions